Satsuma Pharmaceuticals, Inc. Common Stock
STSA
STSA was delisted on the 7th of June, 2023.
0 hedge funds and large institutions have $0 invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 31 closing their positions.
100% less funds holding
Funds holding: 31 → 0 (-31)
100% less capital invested
Capital invested by funds: $12.7M → $0 (-$12.7M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 31
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$4.5M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$4.13M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$1.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$643K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$289K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| – | -$5.54K | -7,932 | Closed |
|
27
Citadel Advisors
Miami,
Florida
| – | -$3.77K | -5,397 | Closed |
|
28
UBS Group
Zurich,
Switzerland
| – | -$1.27K | -1,815 | Closed |
|
29
Group One Trading
Chicago,
Illinois
| – | -$311 | -445 | Closed |
|
30
Wells Fargo
San Francisco,
California
| – | -$130 | -185 | Closed |
|
31
Citigroup
New York
| – | -$6 | -8 | Closed |
|
STSA Hedge Fund Activity: Q2 2023 in Review
0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q2 2023, worth a combined $0 — down 100% from $12.7M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of STSA and 0 opened new positions — a net loss of 31 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BML Capital Management, exiting entirely with an estimated $4.5M sold.
- 0 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q2 2023, down from 31 in Q1 2023.
- Funds reported $0 of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q2 2023 and 31 closed out, a net change of -31 holders.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q2 2023 was BML Capital Management, an estimated $4.5M sold.
Based on aggregated 13F filings for Q2 2023.